Augmented hyper-CVAD based on dose-intensified vincristine, dexamethasone, and asparaginase in adult acute lymphoblastic leukemia salvage therapy

Clinical Lymphoma, Myeloma and Leukemia

Volumn 11, Issue 1, 2011, Pages 54-59

  Faderl, Stefan ^a   Thomas, Deborah Ann ^a   O'Brien, Susan ^a   Ravandi, Farhad ^a   Garcia Manero, Guillermo ^a   Borthakur, Gautam ^a   Ferrajoli, Alessandra ^a   Verstovsek, Srdan ^a   Ayoubi, Mohamed ^a   Rytting, Michael ^a   Feliu, Jennie ^a   Kantarjian, Hagop M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

ALL; Chemotherapy; Myelosuppression; Pegaspargase

Indexed keywords

ACETAZOLAMIDE; AMINOTRANSFERASE; AMYLASE; ANTIFUNGAL AGENT; ANTIVIRUS AGENT; ASPARAGINASE; ASPARAGINASE MACROGOL; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; FLUCONAZOLE; FOLINATE CALCIUM; MESNA; METHOTREXATE; PREDNISONE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TRIACYLGLYCEROL LIPASE; VALACICLOVIR; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ANAPHYLAXIS; ANTIBIOTIC PROPHYLAXIS; ARTICLE; BACTERIAL INFECTION; BLOOD CLOTTING DISORDER; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER MORTALITY; CANCER REGRESSION; CANCER RESISTANCE; CANCER SURVIVAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DRUG ERUPTION; HUMAN; HYPERTRANSAMINASEMIA; INFECTION PREVENTION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; MYCOSIS; OVERALL SURVIVAL; PANCREATITIS; PROGRESSION FREE SURVIVAL; SIDE EFFECT; STEM CELL TRANSPLANTATION; SURVIVAL TIME; VIRUS INFECTION;

EID: 79953727884     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.3816/CLML.2011.n.007     Document Type: Article

References (17)

1. Nachman J. Clinical characteristics, biologic features and outcome for young adult patients with acute lymphoblastic leukaemia. Br J Haematol 2005; 130:166-73. (Pubitemid 41602517)
2. Stock W, La M, Sanford B, et al. What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies. Blood 2008; 112:1646-54.
3. DeAngelo DJ, Dahlberg S, Silverman LB, et al. A multicenter phase II study using a dose intensified pediatric regimen in adults with untreated acute lymphoblastic leukemia. Blood 2007; 110: (abstract 587).
4. Rytting M, Thomas DA, Franklin AR, et al. Pediatric-based therapy for young adults with newly diagnosed lymphoblastic leukemia. Blood 2009; 114: (abstract 2037).
5. Rijneveld AW, van der Holt B, Daenen SM, et al. High dose intensive chemotherapy, as is standard in childhood leukemia, is feasible and efficacious in adult with acute lymphoblastic leukemia (ALL) up to the age of 40: results from the Dutch-Belgian HOVON-70 study. Blood 2009; 114: (abstract 323).
6. Douer D, Watkins C, Mark L, et al. Multiple doses of intravenous pegylated asparaginase with a "pediatric-like" protocol in adults with newly diagnosed acute lymphoblastic leukemia (ALL): toxicity, clinical outcome and low rate of anti asparaginase antibody formation. Blood 2009; 114: (abstract 3082).
7. Huguet F, Leguay T, Raffoux E, et al. Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: The GRAALL-2003 study. J Clin Oncol 2009; 27:911-8.
8. Kantarjian H, Thomas D, O'Brien S, et al. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intense regimen, in adult acute lymphoblastic leukemia. Cancer 2004; 101:2788-801. (Pubitemid 39603187)
9. Douer D, Yampolsky H, Cohen LJ, et al. Pharmacodynamics and safety of intravenous pegaspargase during remission induction in adults aged 55 years or younger with newly diagnosed acute lymphoblastic leukemia. Blood 2007; 109:2744-50. (Pubitemid 46482066)
10. Wetzler M, Sanford BL, Kurtzberg J, et al. Effective asparagines depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 9511.Blood 2007; 109:4164-7. (Pubitemid 46743378)
11. Thomas DA, Faderl S, O'Brien S, et al. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer 2006; 106:1569-80.
12. Koller CA, Kantarjian HM, Thomas D, et al. The hyper-CVAD regimen improves outcome in relapsed acute lymphoblastic leukemia. Leukemia 1997; 11:2039-44. (Pubitemid 28043686)
13. Thomas DA, Faderl S, Cortes J, et al. Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood 2004; 103:4396-407. (Pubitemid 38745962)
14. Thomas DA, Kantarjian HM, Faderl S, et al. Chemoimmunotherapy with a modified Hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia. J Clin Oncol 2010; 28:3880-9.
15. Ribera J-M, Oriol A, Sanz M-A, et al. Comparison of the results of the treatment of adolescents and young adults with standard-risk acute lymphoblastic leukemia with the Programa Espanol de Tratamiento en Hematología pediatric-based protocol ALL-96.J Clin Oncol 2008; 26:1843-9.
16. Graham ML. Pegaspargase: a review of clinical studies. Adv Drug Deliv Rev 2003; 55:1293-302. (Pubitemid 37464563)
17. Thomas DA, Rytting M, O'Brien S, et al. Outcome for adolescents and young adults (AYA) with the hyper-CVAD (with or without rituximab) regimens for de novo acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma. Blood 2009; 114: (abstract 3084).